person · Reporting owner
PATEL DHAVALKUMAR DHIRAJLAL
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sana Biotechnology, Inc.SANA · Entity 4870 | EVP, Chief Scientific Officer | August 26, 2026 | August 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sana Biotechnology, Inc.
Report date August 26, 2026 · Filed August 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 183,352 |
Ending reported balance
After 2026-08-27 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-26 · Exercise / conversion · Acquired 125,000 · Balance 224,510 Row 2 · 2026-08-27 · Tax withholding · Disposed 41,158 · Balance 183,352 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 250,000 |
Reported balance
After 2026-08-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-26 · Exercise / conversion · Disposed 125,000 · Balance 250,000 F1: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechology, Inc. ("Sana") common stock. F2: The award vested as to 25% of the restricted stock units on each of August 26, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of August 26, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechology, Inc. ("Sana") common stock.
F2: The award vested as to 25% of the restricted stock units on each of August 26, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of August 26, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 27, 2026 Filed Aug 27, 2026 20:21 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Tax withholdingCommon Stock | 41,158 | $4.11 | $169,159.38 |
DisclosureSEC source: 0002115339-26-000004 · primarydocument.xml · nonDerivative · entry 2 PATEL DHAVALKUMAR DHIRAJLAL · CIK 0002115339 · EVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,352 Read SEC document |
| August 26, 2026 Filed Aug 27, 2026 20:21 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionRestricted Stock Units · Derivative | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002115339-26-000004 · primarydocument.xml · derivative · entry 3 PATEL DHAVALKUMAR DHIRAJLAL · CIK 0002115339 · EVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 125,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechology, Inc. ("Sana") common stock. F2 · derivative.exercise_date: The award vested as to 25% of the restricted stock units on each of August 26, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of August 26, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. F2 · derivative.expiration_date: The award vested as to 25% of the restricted stock units on each of August 26, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of August 26, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. Read SEC document |
| August 26, 2026 Filed Aug 27, 2026 20:21 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionCommon Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002115339-26-000004 · primarydocument.xml · nonDerivative · entry 1 PATEL DHAVALKUMAR DHIRAJLAL · CIK 0002115339 · EVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.